Trial Profile

Qsymia (Phentermine-topiramate) to Reduce Binge Eating/Purging in Patients With Bulimia Nervosa and Binge Eating Disorder

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Phentermine/topiramate (Primary)
Indications Binge-eating disorder; Bulimia nervosa
Focus Therapeutic Use

Most Recent Events

01 Feb 2020 Status changed from recruiting to discontinued, according to results published in the International Journal of Eating Disorders.
20 Nov 2019 According to a VIVUS media release, results from the study have been published online in the International Journal of Eating Disorders.
20 Nov 2019 Results presented in a VIVUS media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com